Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

The Conversation

Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients

Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to proposals made by the National Institute for Health and Care Excellence (Nice). Previously, it was only available on the NHS for patients with diabetes.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

3 Healthcare Stocks to Watch as the Aging Population Drives Demand

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding healthcare giants like Eli Lilly and Company (LLY), UnitedHealth Group (UNH), and Merck & Co. (MRK) to their watchlist. Read…

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

With a robust performance, strategic expansions, and strong analyst endorsements, Eli Lilly appears poised for continued growth, making it a compelling investment opportunity.

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

inkl

Read news from The Economist, FT, and more,
with one subscription

Snag This Biotech Stock Before November, Here's Why

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

International Business Times

Eli Lilly's Eczema Drug Gets FDA Approval, Injectable Treatment Available Within Weeks

Eli Lilly's Eczema Drug Gets FDA Approval, Injectable Treatment Available Within Weeks

The new injectable drug, Lebrikizumab, branded as Ebglyss, is approved for treating atopic dermatitis in adults and children aged 12 and older who weigh at least 88 pounds.

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

The Conversation

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.

International Business Times

Should You Follow Insider Buying on This Biotech Penny Stock?

Should You Follow Insider Buying on This Biotech Penny Stock?

With significant insider purchases and high-profile hedge fund interest, AbCellera is one penny stock to watch.

How Is Eli Lilly’s Stock Performance Compared to Other Drug Manufacturer Stocks?

How Is Eli Lilly’s Stock Performance Compared to Other Drug Manufacturer Stocks?

Eli Lilly has recently outperformed the general drug manufacturers industry, and analysts are highly optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Key Ingredient In Weight Loss Drugs Ozempic And Wegovy Cuts Risk Of COVID Death: Report

People being treated with the drugs, which both contain semaglutide, had a 33% lower risk of dying from the disease, study found

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

Shares of mega-cap stocks such as Walmart, Meta Platforms, and Eli Lilly have surged over 40% in 2024, outpacing the broader markets by a wide margin.

International Business Times

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

The Times of India

Weight loss drug Tirzepatide cuts diabetes risk by an astonishing 94%, says study

A new study on the popular weight loss drug Tirzepatide, manufactured by American pharmaceutical company Eli Lilly, has found the drug could dramatically cut the risk of developing type 2 diabetes in obese or overweight people with prediabetes, compared with a placebo.

Get all your
news in one place.

100's of premium titles.
One news app.

Tirzepatide Cuts Diabetes Risk By 94% In Prediabetic, Obese Individuals: Trial Results

The three-year trial results revealed that a once-a-week tirzepatide injection for adults who are prediabetic, obese, or overweight reduced their risk of progressing to type 2 diabetes by 94%.

Stocks Finish Lower as Chip and Energy Stocks Decline

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.20%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.24%. US stocks Tuesday gave up an early advance and posted modest losses. Weakness in...

International Business Times

Eli Lilly Weight-loss Drugs Cut Long-term Diabetes Risk: Study

Weight-loss drugs produced and distributed by Eli Lilly show promising results in cutting long-term diabetes risk.

Stocks Pressured by Chip Stocks and Diabetes Device Makers

The S&P 500 Index ($SPX ) (SPY ) today is down -0.18%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.32%. US stocks today gave up an early advance and turned lower. Weakness in chip...

Stocks Waver as the Market Awaits Clues From the Fed About Interest Rates

The S&P 500 Index ($SPX ) (SPY ) today is down -0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.30%. US stocks today are slightly lower this morning, despite a decline in T-note yields....

Stocks See Support from Lower Bond Yields and Positive Corporate News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.22%. US stocks today are mostly higher, with the S&P 500 climbing to a 1-month...

Up 58% YTD, is Eli Lilly Stock Still a Buy?

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

1 … 17 18 19 20

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

375,366 stories

139,323 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play